Dolutegravir and neuropsychiatric adverse events: a continuing debate
- PMID: 28857781
- DOI: 10.1097/QAD.0000000000001596
Dolutegravir and neuropsychiatric adverse events: a continuing debate
Comment on
-
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.AIDS. 2017 Jan 28;31(3):455-457. doi: 10.1097/QAD.0000000000001351. AIDS. 2017. PMID: 28079544 No abstract available.
-
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. AIDS. 2017. PMID: 28079545 No abstract available.
-
Recent observations on intolerance of dolutegravir: differential causes and consequences.AIDS. 2017 Mar 27;31(6):868-870. doi: 10.1097/QAD.0000000000001395. AIDS. 2017. PMID: 28272139 No abstract available.
-
Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe.AIDS. 2017 May 15;31(8):1201-1203. doi: 10.1097/QAD.0000000000001459. AIDS. 2017. PMID: 28441180 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
